scholarly journals Nephrolepis cordifolia: A Review on the fern

2021 ◽  
Vol 23 (10) ◽  
pp. 301-305
Author(s):  
F.Johnsy Mary ◽  
◽  
Dr.M.Senthil Kumar ◽  
E. Vijaykumar ◽  
G. Yadeshwaran ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Oleanolic Acid ◽  
Vibrio Parahaemolyticus ◽  
Hepatocellular Cancer ◽  
World Health ◽  
Drug Resistant ◽  
The World ◽  
Phytochemical Compounds ◽  
Health Organization ◽  
Phytochemical Components

Worldwide, not only is microbiological drug resistance increasing, but so is the burden of liver disease, with approximately 1 million deaths due to liver cirrhosis each year, as well as another 1 million deaths due to viral hepatitis and hepatocellular cancer, according to the World Health Organization (WHO). Many studies have discovered that plant-based phytochemical components such as oleanolic acid, eugenol, and -ionone are effective against a variety of drug-resistant microorganisms, including Streptococcus pneumoniae, Methicillinresistant Staphylococcus aureus (MRSA), and Vibrio parahaemolyticus, among others, and that oleanolic acid and -sitosterol derivatives are In the Himalayan wild fern, Nephrolepis cordifolia, all of these compounds have been shown to be beneficial. A variety of phytochemical compounds found naturally in the Himalayan wild fern Nephrolepis cordifolia (Pani Amla) were investigated in this study, with particular emphasis on their antibacterial, antifungal, anticancer (anti-tumour), and hepatoprotective properties.

scholarly journals TB Elimination Requires Discovery and Development of Transformational Agents

2020 ◽  
Vol 10 (7) ◽  
pp. 2605 ◽  
Author(s):  
Christian Lienhardt ◽  
Mario C. Raviglione
Keyword(s):  
Rapid Detection ◽  
Susceptibility Testing ◽  
Drug Susceptibility ◽  
Drug Susceptibility Testing ◽  
New Drugs ◽  
World Health ◽  
Drug Resistant ◽  
The World ◽  
Health Organization ◽  
Combination Regimens

The World Health Organization (WHO) End Tuberculosis (TB) Strategy has set ambitious targets to reduce 2015 TB incidence and deaths by 80% and 90%, respectively, by the year 2030. Given the current rate of TB incidence decline (about 2% per year annually), reaching these targets will require new transformational tools and innovative ways to deliver them. In addition to improved tests for early and rapid detection of TB and universal drug-susceptibility testing, as well as novel vaccines for improved prevention, better, safer, shorter and more efficacious treatments for all forms of TB are needed. Only a handful of new drugs are currently in phase II or III clinical trials, and a few combination regimens are being tested, mainly for drug-resistant TB. In this article, capitalising on an increasingly rich medicine pipeline and taking advantage of new methodological designs with great potential, the main areas where progress is needed for a transformational improvement of treatment of all forms of TB are described.

scholarly journals Impact of nanosystems in Staphylococcus aureus biofilms treatment

2019 ◽  
Author(s):  
Rita M Pinto ◽  
Daniela Lopes-de-Campos ◽  
M Cristina L Martins ◽  
Patrick Van Dijck ◽  
Cláudia Nunes ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Antibiotic Therapy ◽  
Economic Burden ◽  
Surgical Procedure ◽  
Healthcare Systems ◽  
World Health ◽  
Small Particles ◽  
The World ◽  
New Strategy ◽  
Health Organization

ABSTRACT Staphylococcus aureus (S. aureus) is considered by the World Health Organization as a high priority pathogen for which new therapies are needed. This is particularly important for biofilm implant-associated infections once the only available treatment option implies a surgical procedure combined with antibiotic therapy. Consequently, these infections represent an economic burden for Healthcare Systems. A new strategy has emerged to tackle this problem: for small bugs, small particles. Here, we describe how nanotechnology-based systems have been studied to treat S. aureus biofilms. Their features, drawbacks and potentialities to impact the treatment of these infections are highlighted. Furthermore, we also outline biofilm models and assays required for preclinical validation of those nanosystems to smooth the process of clinical translation.

scholarly journals GeneXpert MTB/RIF Assay for Rapid Identification of Mycobacterium Tuberculosis and Rifampicin Resistance Directly from Sputum Sample

2017 ◽  
Vol 7 (2) ◽  
pp. 86-89 ◽  
Author(s):  
Nourjahan Laskar ◽  
Md Akram Hossain ◽  
Jannatul Fardows ◽  
Mominur Rahman
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Sputum Sample ◽  
Rapid Identification ◽  
Rapid Diagnosis ◽  
World Health ◽  
Multi Drug Resistance ◽  
Drug Resistant ◽  
Resistant Tuberculosis ◽  
The World ◽  
Health Organization

Background: The World Health Organization has endorsed the use of molecular methods for the detection of tuberculosis (TB) and drug resistant TB as a rapid method. In Bangladesh, the Xpert MTB/RIF assay has been implemented into reference laboratories for diagnosis of TB and also MDR TB.Objective: Drug resistant tuberculosis has long been a common problem prevailing in our country. The present study focused on the rapid identification of Mycobacterium tuberculosis as well as drug resistance.Materials and Methods: Sputum samples from a total of 107 cases, assumed as multi-drug resistance tuberculosis, were studied through GeneXpert assay.Results: Out of 107 cases, 91 (85.05%) were detected having M. tuberculosis ? 64 (59.81%) were rifampicin sensitive and 27 (25.23%) were rifampicin resistant. The sensitivity and specificity of the GeneXpert are 87.64% and 75% respectively.Conclusion: GeneXpert assay can be considered for the rapid diagnosis of drug resistant tuberculosis.J Enam Med Col 2017; 7(2): 86-89

scholarly journals Tuberculosis drug resistance in Canada, 1998 to 2000

2001 ◽  
Vol 12 (3) ◽  
pp. 141-143
Author(s):  
Melissa D Phypers ◽  
Linda Panaro ◽  
Penny Nault
Keyword(s):  
World Health ◽  
Drug Resistant ◽  
First Line ◽  
International Union ◽  
The World ◽  
Resistant Strains ◽  
Health Organization ◽  
Global Threat ◽  
Drug Resistant Strains ◽  
And Control

The emergence of drug-resistant strains of tuberculosis (TB) is a global threat to TB prevention and control efforts. A recent study conducted by the World Health Organization (WHO) and the International Union Against Tuberculosis and Lung Disease found strains of TB resistant to first-line anti-TB drugs in all countries surveyed (1). The WHO estimates that 50 million people are infected with strains of drug-resistant TB (2).

The Burden of Stroke in Nigeria

2008 ◽  
Vol 3 (4) ◽  
pp. 290-292 ◽  
Author(s):  
Kolawole Wasiu Wahab
Keyword(s):  
Case Fatality Rate ◽  
Case Fatality ◽  
World Health ◽  
Drug Resistant ◽  
Day Case ◽  
High Quality ◽  
High Quality Research ◽  
Current Prevalence ◽  
The World ◽  
Health Organization

Stroke is a leading cause of morbidity and mortality worldwide, and it is likely to worsen in developing countries over the next two decades based on the projections by the World Health Organization (WHO). With the current scourge of HIV/AIDS and the battle against other communicable diseases like multi-drug resistant malaria and tuberculosis; Nigeria, the most populous black nation in the world, stands to risk the further straining of its resources as a result of the increasing prevalence of stroke and other cardiovascular diseases due to epidemiological transition. The current prevalence of stroke in Nigeria is 1.14 per 1000 while the 30-day case fatality rate is as high as 40%. Management of the disease is largely conservative while there is little or no funding for high-quality research. Primary prevention is the key to reducing the burden of the disease in a country with such poor resources.

scholarly journals World Health Organization reports highest rates of drug-resistant tuberculosis to date

2008 ◽  
Vol 13 (12) ◽  
pp. 11-12 ◽  
Author(s):  
Collective Editorial team
Keyword(s):  
Drug Resistance ◽  
World Health Organization ◽  
Multidrug Resistant ◽  
World Health ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Fourth Report ◽  
The World ◽  
Health Organization

On 26 February 2008, the World Health Organization (WHO) published its fourth report on the global situation regarding drug resistance in tuberculosis (TB). The report, based on information collected between 2002 and 2006 on 90,000 TB patients in 81 countries, found that 5.3% of the nine million new cases of TB each year are multidrug-resistant (MDR). This is the highest rate yet recorded.

scholarly journals World TB Day 2018: The Challenge of Drug Resistant Tuberculosis

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 217 ◽  
Author(s):  
Ankur Gupta-Wright ◽  
Gillian S Tomlinson ◽  
Molebogeng X Rangaka ◽  
Helen A Fletcher
Keyword(s):  
Mycobacterium Tuberculosis ◽  
World Health Organization ◽  
Scientific Community ◽  
World Health ◽  
Drug Resistant ◽  
Free World ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
The World ◽  
Health Organization

On 24th March, the world commemorates the day in 1882 when Dr Robert Koch announced his discovery of Mycobacterium tuberculosis (MTB). Over 130 years later, tuberculosis (TB) continues to affect individuals, communities, and entire health systems and economies. Koch unsuccessfully tried to ‘cure’ TB, and despite major advances in other areas of medicine, control of TB remains elusive- in 2016 TB was the leading infectious cause of death. The STOP TB partnership and World Health Organization (WHO) have announced their theme for World TB Day 2018 “Wanted: Leaders for a TB-Free World. You can make history. End TB.” This theme recognizes that TB is much larger than any one person, institute or discipline of research, and provides an opportunity for us to reflect on the major challenges and consider how we, as a scientific community, can work together and take the lead to address the global crisis of drug-resistant TB (DR-TB).

Sign in / Sign up

Export Citation Format

Share Document